Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06895928 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06939270 | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05749432 | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06925659 | A Study of QLM2011 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 172 | Qilu Pharmaceutical (Hainan) Co., Ltd.INDUSTRY | 0 | Apr 17, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT05473624 | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06927349 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06928363 | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 212 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 0 | Apr 15, 2025 | clinicaltrials |
| NCT06094556 | An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 240 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | enrolling by invitation | — | 50 | Allogene TherapeuticsINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04762862 | QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy(QUANTACT) | enrolling by invitation | — | 1,200 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06096974 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | recruiting | Phase 1 | 60 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06710379 | A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 68 | Adcentrx TherapeuticsINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06916442 | Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy(GZMB_PET) | not yet recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05544240 | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 20 | Williams Cancer FoundationOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06885645 | First-In-Human Study in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05477849 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors | recruiting | Phase 1 | 30 | Shanghai Virogin Biotech Co., Ltd.INDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05916248 | Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 34 | Ruijin HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06150365 | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 32 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06897228 | PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | recruiting | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04877717 | A Study of SHR-A1904 in Patients With Advanced Solid Cancer | active not recruiting | Phase 1 | 107 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06894082 | Study of Radiology Manipulator Work Validation by the Radiologist(Cimer) | recruiting | — | 87 | Institut Paoli-CalmettesOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05970016 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 56 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06889675 | First in Human Study of YB1-X7 Injection | not yet recruiting | N/A | 36 | Shanghai Salvectors Biotechnology LTD.INDUSTRY | 0 | Mar 21, 2025 | clinicaltrials |
| NCT05828459 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | recruiting | Phase 1 | 150 | Onward TherapeuticsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT06873854 | A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours | not yet recruiting | Phase 2 | 84 | LaNova Medicines LimitedINDUSTRY | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05142423 | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06707610 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors | recruiting | Phase 1 | 234 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT06872580 | A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 12, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06730386 | A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 100 | AkesoINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06443489 | A Trial of SHR-4849 in Advanced Solid Tumors | recruiting | Phase 1 | 80 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT03943004 | Trial of DFP-14927 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06350539 | Personalized Models for Cancer Research | recruiting | — | 500 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05749627 | Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors | recruiting | N/A | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2025source: clinicaltrials